首页> 美国卫生研究院文献>Journal of Korean Neurosurgical Society >Diffuse Intrinsic Pontine Glioma : Clinical Features Molecular Genetics and Novel Targeted Therapeutics
【2h】

Diffuse Intrinsic Pontine Glioma : Clinical Features Molecular Genetics and Novel Targeted Therapeutics

机译:弥漫性内源性脑胶质瘤:临床特征分子遗传学和新型靶向治疗。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diffuse intrinsic pontine glioma (DIPG) is a deadly paediatric brain cancer. Transient response to radiation, ineffective chemotherapeutic agents and aggressive biology result in rapid progression of symptoms and a dismal prognosis. Increased availability of tumour tissue has enabled the identification of histone gene aberrations, genetic driver mutations and methylation changes, which have resulted in molecular and phenotypic subgrouping. However, many of the underlying mechanisms of DIPG oncogenesis remain unexplained. It is hoped that more representative in vitro and preclinical models–using both xenografted material and genetically engineered mice–will enable the development of novel chemotherapeutic agents and strategies for targeted drug delivery. This review provides a clinical overview of DIPG, the barriers to progress in developing effective treatment, updates on drug development and preclinical models, and an introduction to new technologies aimed at enhancing drug delivery.
机译:弥漫性桥脑神经胶质瘤(DIPG)是一种致命的小儿脑癌。对辐射的短暂反应,无效的化学治疗剂和侵略性生物学会导致症状快速发展和预后不良。肿瘤组织可用性的提高使得能够鉴定组蛋白基因畸变,遗传驱动基因突变和甲基化变化,从而导致了分子和表型亚群的出现。但是,DIPG肿瘤发生的许多潜在机制仍无法解释。希望通过使用异种移植材料和基因工程小鼠,建立更具代表性的体外和临床前模型,将能够开发新型化疗药物和靶向药物递送策略。这篇综述提供了DIPG的临床概况,开发有效治疗的障碍,药物开发和临床前模型的最新进展,以及旨在增强药物输送的新技术的介绍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号